Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05082610 · ClinicalTrials.gov registry record · Phase 1
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Hummingbird Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05082610 is a Phase 1 study that has completed, run by Hummingbird Bioscience. The registered enrollment target is 48 participants.
The verdict
NCT05082610, a Phase 1 study, has completed, sponsored by Hummingbird Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or without pembrolizumab KEYTRUDA®, in patients with advanced solid tumors (i.e., locally advanced and unresectable, or metastatic).
Interventions
- DRUG Pembrolizumab
- DRUG HMBD-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-02-28 |
| Est. Completion | 2024-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05082610
The ClinicalTrials.gov registry entry for NCT05082610 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hummingbird Bioscience, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05082610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05082610 about?
NCT05082610 is a clinical study titled "A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors". This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or without pembrolizumab KEYTRUDA®, in patients with advanced solid tumors (i....
What is the current status of trial NCT05082610?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-02-28. Estimated completion is 2024-12-03.
What interventions are being tested in trial NCT05082610?
The interventions under investigation include: Pembrolizumab (DRUG), HMBD-002 (DRUG).
Who is sponsoring clinical trial NCT05082610?
This trial is sponsored by Hummingbird Bioscience, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.